Edesa Biotech Reports Q3 2026 Financial Results

What Happened

• On August 13, 2026, Edesa Biotech, Inc. (EDSA) announced its financial results for the three and nine months ended June 30, 2026 via a press release attached to an 8-K (Exhibit 99.1). The 8-K states the Earnings Release is furnished, not “filed,” under the Exchange Act. The report was signed by CFO Peter J. Weiler.

Key Details

• Filing date: August 13, 2026.
• Period covered: three and nine months ended June 30, 2026.
• Disclosure form: Press release attached as Exhibit 99.1 (information furnished, not filed).
• Authorized signatory: Peter J. Weiler, Chief Financial Officer.

Why It Matters

• This 8-K signals that Edesa has released its latest quarterly results and related information (earnings, revenue, quarterly results) that investors should review to assess the company’s recent performance and short-term outlook.
• Because the release is furnished rather than filed, the company notes the earnings disclosure is not subject to Section 18 liability and may not be automatically incorporated by reference into other SEC filings. Investors should read the attached press release (Exhibit 99.1) and subsequent SEC filings for the detailed revenue, earnings, cash position, and any management commentary or guidance.